Miscellaneous Ob/Gyn conditions:
Indications for VYLEESI:
Acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women and is not due to a coexisting medical or psychiatric condition, problems within the relationship, or adverse effect of a medication or other drug substance.
Limitations of Use:
Not for HSDD in postmenopausal women or in men. Not for sexual performance enhancement.
Give by SC inj in abdomen or thigh as needed, at least 45mins before sexual activity. 1.75mg as a single daily dose. Max 1 dose per 24hrs or 8 doses per month. Discontinue if no improvement after 8 weeks.
Uncontrolled hypertension. Known cardiovascular disease.
Consider patient’s cardiovascular risk before initiating and periodically during treatment, and ensure BP is well-controlled. High risk for cardiovascular disease: not recommended. Consider discontinuing if hyperpigmentation develops. Severe hepatic or renal impairment. Pregnancy: not recommended; discontinue if suspected. Nursing mothers.
Melanocortin receptor agonist.
Avoid concomitant oral drugs that depend on threshold concentrations for efficacy (eg, antibiotics). Consider discontinuing if there is a delayed effect of concomitant oral drug when a quick onset is desired (eg, indomethacin). Avoid use with oral naltrexone-containing products intended to treat alcohol or opioid addiction.
Nausea, flushing, inj site reactions, headache, vomiting, cough, fatigue, hot flush, paraesthesia, dizziness, nasal congestion; focal hyperpigmentation (esp. with dark skin), transient increases in BP and reduction in HR.
Generic Drug Availability:
Single-dose prefilled autoinjectors—4